Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium Ga 68 tilmanocept is a radiopharmaceutical diagnostic agent consisting of the synthetic molecule tilmanocept labeled with the positron-emitting radioisotope gallium-68. Tilmanocept is a mannosylated dextran compound that binds with high affinity to CD206 (macrophage mannose receptor), which is highly expressed on the surface of macrophages and dendritic cells, particularly in lymphatic tissue. When labeled with gallium-68, it enables targeted PET imaging for sentinel lymph node mapping and detection of metastatic spread in cancers such as thyroid carcinoma and endometrial carcinoma. The agent provides high specificity for sentinel nodes, facilitating image-guided tumor resection and lymphadenectomy. It has also been investigated for imaging atherosclerotic plaques due to its ability to target macrophage-rich tissues[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium Ga 68 tilmanocept.